HLA-G–Presented Peptides: Defining a New Class of Neoantigen Targets for Hard-to-Treat Solid Tumours
- Why HLA-G? Restricted expression in healthy tissues and enrichment in hypoxic, advanced tumours
- Enabling technologies for high-confidence identification of HLA-G–bound peptide repertoires
- Translational insights from mapping the HLA-G immunopeptidome in pancreatic ductal adenocarcinoma (PDAC)